Not available
Quote | Cullinan Oncology Inc. (OTCMKTS:CGEM)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.02 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 10/25/2019 04:53:23 pm |
News | Cullinan Oncology Inc. (OTCMKTS:CGEM)
2024-03-14 12:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cullinan Oncology (NASDAQ: CGEM ) just reported results for the fourth quarter of 2023. Cullinan Oncology reported earnings per share of -54 cents. This was above the anal...
2024-03-14 11:37:57 ET More on Cullinan Oncology Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings data for Cullinan Oncology Financial information for Cullinan Oncology Read the full article on Seeking Alpha For further det...
Message Board Posts | Cullinan Oncology Inc. (OTCMKTS:CGEM)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CGEM News Article - Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for | whytestocks | investorshangout | 06/23/2022 7:41:00 PM |
whytestocks: $CGEM News Article - Cullinan Oncology to Participate in Upcoming Virtual Healthcare Co | whytestocks | investorshangout | 04/05/2022 12:11:01 PM |
whytestocks: $CGEM News Article - Cullinan Oncology to Present at the Barclays Global Healthcare Con | whytestocks | investorshangout | 03/09/2022 9:11:19 PM |
whytestocks: $CGEM News Article - Cullinan Oncology Provides Corporate Update and Reports Second Qua | whytestocks | investorshangout | 08/10/2021 6:05:48 PM |
whytestocks: $CGEM News Article - Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan P | whytestocks | investorshangout | 06/04/2021 2:05:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
OTCMKTS Market:
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma The company is exploring development of its CD19xCD3 T cel...